Potential type 1 diabetes treatment mechanism confirmed
26 Aug 2008

The mechanism behind a potential new therapy for type 1 diabetes has been confirmed by staff from Massachusetts General Hospital (MGH) in Boston, USA.

Web resource Eurekalert notes that a team found that blocking a metabolic pathway regulating the immune system specifically eliminated immune cells which react against a patient's own tissues.

The team previously discovered a technique which reversed diabetes in trials on mice.

The researchers found that triggering the expression of immune system modulator tumour necrosis factor led to the death of T cells responsible for the destruction of insulin producing pancreatic islets.

After the treatment, the mice were able to regenerate healthy islet cells which produced regular levels of insulin.

Due to appear in the journal Proceedings of the National Academy of Sciences, the current research is the first demonstration of this technique in human cells.

Commenting on the study, Dr Denise Faustman, director of the MGH immunobiology laboratory, said: "Our studies in mice showed that we could selectively kill the defective autoimmune cells that were destroying insulin-producing islets. These results show that the same selective destruction can occur in humans cells."

Login and visit the Diabetes Knowledge Centre

Print Article    Bookmark

• Porridge could limit type-2 diabetes side effects 09/01/09
• Men with type-2 diabetes at greater risk of cardiovascular death 06/01/09
• Decline in mental processing affects diabetes patients, study reveals 05/01/09
• Leptin study could lead to new diabetes treatment 23/12/08
• Symptomless virus linked with type 1 diabetes 19/12/08

• PRANDIN Tablets - 49.44%
  ... in patients with Type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in Type 2 diabetes patients who are not ...
  
  
• DDAVP - 49.42%
  ... and treatment of vasopressin-sensitive cranial diabetes insipidus; establishing renal concentration capacity. DDAVP Tablets: Treatment of vasopressin-sensitive cranial diabetes insipidus; treatment of post-hypophysectomy polyuria/ polydipsia. DDAVP/Desmopressin Injection: Cranial diabetes insipidus ...
  
  
• JANUVIA Film-Coated Tablets - 47.95%
  JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin when diet and exercise, plus metformin do not provide adequate glycaemic control. For patients with type 2 diabetes mellitus in whom use of a PPAR? agonist (i.e. a ...
  
  
• EXUBERA - 47.95%
  ... for the treatment of adult patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic agents and requiring insulin therapy. EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, in addition to long or intermediate acting ...
  
  
• NOCUTIL - 47.95%
  Treatment of idiopathic central diabetes insipidus, or diabetes insipidus occurring after hypophysectomy, cranial trauma, or surgery in the pituitary region ...
  
  
• GLUCOPHAGE - 47.95%
  Non-insulin dependent (type II) diabetes either alone or with sulphonylureas. Adjuvant therapy in insulin-dependent diabetes, particularly in the obese ...